Incyte Corporation — Q1 2021 Form 10-Q
Business and period: Biopharmaceutical company reporting the three months ended March 31, 2021, compared with Q1 2020. Its portfolio includes JAKAFI, ICLUSIG, PEMAZYRE and co-commercialized MONJUVI; it also earns royalties on partner products. Incyte reports one operating segment.
Financial performance
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Total revenue | $604.7m | $568.5m | Up 6.4% |
| Product revenue | $504.8m | $486.7m | Up 3.7% |
| Product royalty revenue | $99.9m | $81.8m | Up 22.2% |
| Operating income (loss) | $98.8m | ($664.0m) | Prior period included major MorphoSys collaboration expense |
| Net income (loss) | $53.5m | ($720.6m) | EPS $0.24 vs. ($3.33) |
| Operating cash flow | $206.1m | ($683.4m) | Improved $889.5m, primarily reflecting the $750m MorphoSys upfront payment in Q1 2020 and working-capital changes |
| Investing cash flow | ($59.8m) | ($108.6m) | Included $48.1m of capital expenditures |
| Financing cash flow | $12.8m | $2.5m | Mainly stock-plan proceeds, partly offset by contingent-consideration payments |
Revenue mix: JAKAFI $465.7m (up 1.4%); ICLUSIG $25.6m (down 5.9%); PEMAZYRE $13.5m (launched in 2020). Royalties comprised JAKAVI $65.6m, OLUMIANT $32.3m and TABRECTA $2.0m. Management attributed JAKAFI growth to an $11.1m price contribution, partly offset by a $4.9m volume decline, including fewer new patient starts related to COVID-19 and prior-year channel stocking.
Expenses and margins: Research and development was $306.9m versus $1,085.3m; the prior-year figure included the $750m MorphoSys upfront payment. Selling, general and administrative expense increased to $153.8m from $111.1m, reflecting higher staffing, dermatology launch preparation and other costs, including a legal reserve. Product cost was $29.2m. The filing does not present gross margin; a simple calculation using product revenue less product cost implies approximately 94.2%, but this is not a company-reported margin and excludes royalty revenue.
Financial position and liquidity
- Cash and cash equivalents were $1.670bn; current marketable securities were $292.4m and long-term investments $202.2m. Cash, cash equivalents and marketable securities totaled approximately $1.96bn.
- Current assets were $2.450bn and current liabilities $623.9m (derived current ratio approximately 3.9x). Total assets were $3.661bn; total liabilities $933.6m; stockholders’ equity $2.728bn.
- Finance lease liabilities totaled $34.5m; the filing reports no conventional borrowing balance in the presented balance sheet. Acquisition-related contingent consideration was $263.0m, primarily future ICLUSIG royalties payable to Takeda.
- Accumulated deficit was $1.673bn. Management stated existing cash, investments and operating cash flow should meet capital needs for the foreseeable future.
Material changes, outlook and risks
- The Q1 2020 loss is not a like-for-like indicator of operating performance: it included a $750m MorphoSys upfront expense. Q1 2021 also included a $27.7m unrealized loss on long-term investments, versus $48.1m in Q1 2020.
- Incyte reported no specific full-year financial guidance in the supplied filing text. Key near-term regulatory events included FDA Priority Review of ruxolitinib cream for atopic dermatitis, with a June 21, 2021 action date, and Priority Review of ruxolitinib for steroid-refractory chronic GVHD. Retifanlimab’s anal-cancer application was also under FDA Priority Review.
- Pipeline and commercial execution remain uncertain. The filing notes COVID-related effects on new patient starts and clinical operations; supply-chain reliance on limited or third-party manufacturers; competition, pricing and reimbursement pressures; and dependence on JAKAFI, which remains a substantial share of revenue.
- COVID-19 trial outcomes were mixed or negative: ruxolitinib did not prevent complications in RUXCOVID and did not reduce overall mortality in a ventilated-patient study; baricitinib missed COV-BARRIER’s primary endpoint, although a mortality reduction was reported. The filing also describes prior development setbacks, including itacitinib’s acute-GVHD Phase III failure.
- Incyte disclosed a DOJ-related matter concerning speaker and patient-assistance programs. It denies improper claims, reports a settlement in principle with the DOJ Civil Division, and recorded a $13.2m reserve. No trial date had been set.
- Market and valuation exposures include fair-value changes in publicly traded collaboration partners and Level 3 contingent consideration. Incyte reported a $27.7m investment loss in Q1. It also cited customer concentration: four product customers represented 35% of accounts receivable at quarter-end.
Important facts for investors to verify
- Whether JAKAFI demand, new patient starts and channel inventory normalize, and how much growth depends on price increases versus volume.
- Regulatory outcomes and commercial uptake for ruxolitinib cream, chronic-GVHD ruxolitinib, retifanlimab and newer products, including the conditions attached to any accelerated approvals.
- Clinical progress and spending across the pipeline, including the consequences of COVID-19 trial results and any further program discontinuations.
- Durability of cash generation and capital spending on the Delaware headquarters and Swiss manufacturing facility, both expected to become operational in the first half of 2022.
- Resolution and final cost of the DOJ matter; movement in sales-allowance accruals, contingent consideration and investment valuations; and developments in JAKAFI patent or generic challenges.